PriceTargets.com logo

Praxis Precision Medicines - PRAX Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $146.33
  • Forecasted Upside: 97.35%
  • Number of Analysts: 9
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
$74.15 As of 12/3/2024 01:01 PM ET
▼ -3.71 (-4.76%)

This chart shows the closing price for PRAX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Praxis Precision Medicines Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PRAX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PRAX

Analyst Price Target is $146.33
▲ +97.35% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Praxis Precision Medicines in the last 3 months. The average price target is $146.33, with a high forecast of $270.00 and a low forecast of $48.00. The average price target represents a 97.35% upside from the last price of $74.15.

This chart shows the closing price for PRAX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 9 investment analysts is to moderate buy stock in Praxis Precision Medicines. This rating has held steady since May 2023, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/11/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/9/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
12/8/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/7/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/5/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/3/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/2/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/2/2024

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/7/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$151.00 ➝ $151.00
11/7/2024HC WainwrightReiterated RatingBuy ➝ Buy$120.00 ➝ $120.00
10/31/2024OppenheimerBoost TargetOutperform ➝ Outperform$143.00 ➝ $163.00
9/10/2024HC WainwrightReiterated RatingBuy ➝ Buy$120.00 ➝ $120.00
9/4/2024OppenheimerReiterated RatingOutperform ➝ Outperform$134.00 ➝ $143.00
9/3/2024HC WainwrightReiterated RatingBuy ➝ Buy$120.00 ➝ $120.00
9/3/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$145.00 ➝ $145.00
8/15/2024HC WainwrightBoost TargetBuy ➝ Buy$105.00 ➝ $120.00
8/14/2024GuggenheimBoost TargetBuy ➝ Buy$155.00 ➝ $170.00
8/14/2024OppenheimerReiterated RatingOutperform ➝ Outperform$134.00 ➝ $134.00
8/14/2024WedbushBoost TargetNeutral ➝ Neutral$40.00 ➝ $48.00
8/12/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$145.00 ➝ $145.00
8/5/2024OppenheimerInitiated CoverageOutperform$134.00
7/1/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$270.00 ➝ $270.00
6/24/2024Needham & Company LLCInitiated CoverageBuy$145.00
6/18/2024GuggenheimInitiated CoverageBuy$155.00
5/16/2024Truist FinancialReiterated RatingBuy ➝ Buy$150.00 ➝ $150.00
5/14/2024HC WainwrightReiterated RatingBuy ➝ Buy$105.00
5/1/2024Robert W. BairdInitiated CoverageOutperform$117.00
4/26/2024HC WainwrightReiterated RatingBuy ➝ Buy$105.00
3/26/2024Jefferies Financial GroupBoost TargetBuy ➝ Buy$75.00 ➝ $128.00
3/26/2024HC WainwrightReiterated RatingBuy ➝ Buy$105.00
3/6/2024HC WainwrightReiterated RatingBuy ➝ Buy$105.00
1/12/2024WedbushBoost TargetNeutral ➝ Neutral$16.00 ➝ $29.00
12/5/2023HC WainwrightReiterated RatingBuy ➝ Buy$105.00
12/4/2023Truist FinancialReiterated RatingBuy ➝ Buy$150.00
11/15/2023HC WainwrightReiterated RatingBuy ➝ Buy$105.00
10/3/2023WedbushReiterated RatingNeutral ➝ Neutral$30.00
9/19/2023Truist FinancialInitiated CoverageBuy$150.00
8/10/2023HC WainwrightLower TargetBuy ➝ Buy$225.00 ➝ $105.00
6/2/2023Jefferies Financial GroupInitiated CoverageBuy
5/12/2023HC WainwrightLower Target$240.00 ➝ $225.00
4/14/2023HC WainwrightReiterated RatingBuy$240.00
3/6/2023HC WainwrightReiterated RatingBuy$240.00
3/3/2023William BlairDowngradeOutperform ➝ Market Perform
2/3/2023HC WainwrightBoost TargetBuy$150.00 ➝ $240.00
6/7/2022Piper SandlerLower TargetOverweight$975.00 ➝ $270.00
6/7/2022Bank of AmericaDowngradeBuy ➝ Neutral$60.00
6/7/2022HC WainwrightLower TargetBuy$720.00 ➝ $150.00
6/6/2022WedbushDowngradeOutperform ➝ Neutral$60.00
5/10/2022WedbushLower Target$600.00 ➝ $510.00
12/16/2021HC WainwrightInitiated CoverageBuy$720.00
11/4/2021WedbushLower TargetOutperform$750.00 ➝ $675.00
8/26/2021Bank of AmericaInitiated CoverageBuy$420.00
5/3/2021William BlairInitiated CoverageOutperform
4/26/2021William BlairInitiated CoverageOutperform
1/21/2021WedbushBoost TargetOutperform$765.00 ➝ $915.00
11/11/2020WedbushInitiated CoverageOutperform$600.00
11/10/2020Evercore ISIInitiated CoverageOutperform$825.00
11/10/2020CowenInitiated CoverageOutperform
11/10/2020Piper SandlerInitiated CoverageOverweight$975.00
(Data available from 12/3/2019 forward)

News Sentiment Rating

1.01 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/7/2024
  • 3 very positive mentions
  • 14 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
6/6/2024
  • 10 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/6/2024
  • 4 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
8/5/2024
  • 10 very positive mentions
  • 18 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/4/2024
  • 13 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/4/2024
  • 7 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/3/2024
  • 16 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/3/2024

Current Sentiment

  • 16 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Praxis Precision Medicines logo
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.
Read More

Today's Range

Now: $74.15
Low: $73.88
High: $77.45

50 Day Range

MA: $70.29
Low: $56.55
High: $84.83

52 Week Range

Now: $74.15
Low: $14.77
High: $86.93

Volume

62,801 shs

Average Volume

284,106 shs

Market Capitalization

$1.38 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.67

Frequently Asked Questions

What sell-side analysts currently cover shares of Praxis Precision Medicines?

The following Wall Street analysts have issued research reports on Praxis Precision Medicines in the last year: Guggenheim, HC Wainwright, Jefferies Financial Group Inc., Needham & Company LLC, Oppenheimer Holdings Inc., Piper Sandler, Robert W. Baird, Truist Financial Co., and Wedbush.
View the latest analyst ratings for PRAX.

What is the current price target for Praxis Precision Medicines?

0 Wall Street analysts have set twelve-month price targets for Praxis Precision Medicines in the last year. Their average twelve-month price target is $146.33, suggesting a possible upside of 97.3%. Piper Sandler has the highest price target set, predicting PRAX will reach $270.00 in the next twelve months. Wedbush has the lowest price target set, forecasting a price of $48.00 for Praxis Precision Medicines in the next year.
View the latest price targets for PRAX.

What is the current consensus analyst rating for Praxis Precision Medicines?

Praxis Precision Medicines currently has 1 hold rating and 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for PRAX.

What other companies compete with Praxis Precision Medicines?

Other companies that are similar to Praxis Precision Medicines include Viking Therapeutics, Krystal Biotech, TG Therapeutics, Crinetics Pharmaceuticals and Arcellx. Learn More about companies similar to Praxis Precision Medicines.

How do I contact Praxis Precision Medicines' investor relations team?

Praxis Precision Medicines' physical mailing address is 101 MAIN STREET #1210, CAMBRIDGE MA, 02142. The company's listed phone number is 617-300-8460 and its investor relations email address is [email protected]. The official website for Praxis Precision Medicines is www.praxismedicines.com. Learn More about contacing Praxis Precision Medicines investor relations.